舌癌男性患者的循环催乳素和肿瘤催乳素受体：一项初步研究。

Circulating prolactin and tumoral prolactin receptors in men with tongue cancer: a preliminary study.

作者信息

Patel D D, Bhatavdekar J M, Vora H H, Balar D B

机构信息

Gujarat Cancer & Research Institute, Ahmedabad, India.

出版信息

Eur J Surg Oncol. 1994 Apr;20(2):155-9.

PMID:8181582

Abstract

Pre-therapeutic circulating prolactin levels and tumoral prolactin receptors (PRLR) were determined in 25 male patients with tongue cancer. The patients were divided into PRLR positive (PRLR+) and PRLR negative (PRLR-) groups. The overall survival was statistically non-significant between these two groups of PRLR as well as when considering 2% as the cut-off level. Moreover, no correlation was observed between PRLR status and clinicopathologic prognosticators. Furthermore, patients with < 2% PRLR had significantly higher levels of circulating prolactin than their counterparts (P < 0.05). Patients with PRLR- tumors having hyperprolactinemia (prolactin > 15.0 ng/ml) had unfavourable overall survival (chi 2 = 4.08, df = 1, P < 0.04) than those with normoprolactin (prolactin < 15.0 ng/ml). From this pilot study, it seems that PRLR negativity with hyperprolactinemia could be used as an independent predictor of short-term prognosis in cancer tongue patients.

摘要

对25例男性舌癌患者测定了治疗前循环催乳素水平和肿瘤催乳素受体（PRLR）。患者被分为PRLR阳性（PRLR+）组和PRLR阴性（PRLR-）组。在这两组PRLR之间以及以2%作为临界值时，总生存率在统计学上无显著差异。此外，未观察到PRLR状态与临床病理预后指标之间存在相关性。此外，PRLR<2%的患者循环催乳素水平显著高于其对应患者（P<0.05）。PRLR-肿瘤且伴有高催乳素血症（催乳素>15.0 ng/ml）的患者总生存率（χ2=4.08，自由度=1，P<0.04）比催乳素正常（催乳素<15.0 ng/ml）的患者差。从这项初步研究来看，PRLR阴性伴高催乳素血症似乎可作为舌癌患者短期预后的独立预测指标。